---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-036838"
form_type: "8-K"
ticker: "CRBP"
cik: "0001595097"
company_name: "Corbus Pharmaceuticals Holdings, Inc."
filed_at: "2025-03-11T23:59:59+00:00"
generated_at: "2026-05-24T23:43:08.356173+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Corbus reports Q4 net loss $9.5M, cash $149.1M; pipeline updates on CRB-701, CRB-913, CRB-601

## Summary
- Net loss Q4 2024 $9.5M ($0.78/share) vs $8.0M ($1.81/share) in Q4 2023; full-year loss $40.2M ($3.68/share).
- Cash and investments $149.1M at Dec 31, 2024; expected to fund operations through Q3 2027.
- CRB-701 (Nectin-4 ADC) Phase 1 shows safety and responses in HNSCC, cervical, and mUC; FDA Fast Track for metastatic cervical cancer.
- CRB-913 obesity Ph1 SAD/MAD first dosing expected March 2025; CRB-601 first patient dosed Dec 2024, dose escalation Q4 2025.

## SEC filing metadata
- accession: 0000950170-25-036838
- form_type: 8-K
- ticker: CRBP
- cik: 0001595097
- company_name: Corbus Pharmaceuticals Holdings, Inc.
- filed_at: 2025-03-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595097/000095017025036838/0000950170-25-036838-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595097/000095017025036838/crbp-20250311.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-036838
- JSON: https://secwatch.observer/filing/0000950170-25-036838.json
- Plain text: https://secwatch.observer/filing/0000950170-25-036838.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.